TERMINATION AGREEMENTTermination Agreement • November 4th, 2019 • MyoKardia Inc • Pharmaceutical preparations
This TERMINATION AGREEMENT (“Agreement”) dated as of JULY 17,2019 (the “Effective Date”), is made and entered into by and between MYOKARDIA, INC., a Delaware corporation having an address at 333 Allerton Avenue, South San Francisco, CA 94080, (“MyoKardia”) and AVENTIS, INC., a Pennsylvania corporation (“Sanofi”).
October 4, 2019 PERSONAL & CONFIDENTIAL DELIVERED IN PERSON June LeeTransition Agreement • November 4th, 2019 • MyoKardia Inc • Pharmaceutical preparations • California
This confirms that your employment with MyoKardia, Inc. (the “Company”) will be ending. We appreciate your contributions and wish to make this transition as smooth as possible for both you and the Company. Consistent with that notion, this letter proposes an agreement (the “Agreement”), under which you will continue to be employed by the Company during a Transition Period (defined below) and, thereafter, you will receive Severance Benefits (defined below) if you enter into this Agreement and satisfy the other conditions that are set forth and defined below.
